Antineoplastic Drugs. Antineoplastic Drugs. Herbal Alert. Pharmacology Chapter 51. Green tea

Size: px
Start display at page:

Download "Antineoplastic Drugs. Antineoplastic Drugs. Herbal Alert. Pharmacology Chapter 51. Green tea"

Transcription

1 Antineoplastic Drugs Pharmacology Chapter 51 Carolyn Wright, RN, BSN Ford, S. & Roach, S. (2010). Roach's introductory clinical pharmacology (9 th ed.). Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins. 1 Antineoplastic Drugs Chemotherapy is a term used to refer to therapy with antineoplastic drugs. Cure Control Palliation 2 Herbal Alert Green tea Polyphenols (flavonoids) Antioxidants Benefits Side Effects 3 1

2 CELL CYCLE All cells have a specific pattern (phase) of growth and division Some cells divide and reproduce in a manner of hours, others years. Chemotherapy administered in series of courses Why? 4 Hormones Exact action unclear May counteract effect of male and female hormones in hormone-dependent tumors. Alter the hormonal environment of the cell progestin megestrol (Megace) Breast or endometrial cancer Luprolide (Lupron) Prostate cancer 5 Cell Cycle-Specific Plant Alkaloids Vinca Alkaloids vinblastine sulfate (Velban) Antimetabolites Folic Acid Antagonist methotrexate (Rheumatrex) Antidote = leucovorin (Wellcovorin) 6 2

3 Plant Alkaloids Interferes with or stops cell division. Causes long term fertility problems Additive bone marrow depressive effects when administered with other antineoplastics/radiation 7 Plant Alkaloids Interactions Digoxin Anticoagulants vinblastine sulfate (Velban) increases risk of seizures 8 Antimetabolites Interfere with metabolic functions Inactivate enzymes or alter the structure of DNA and its ability to replicate. Most effective in tx of rapidly dividing neoplastic cells. When administered with other antineoplastic drugs, bone marrow depression is additive. Decreases serum digoxin levels 9 3

4 Antimetabolites Interactions methotrexate (Rheumatrex) NSAIDs = methotrexate toxicity Folic acid may decrease effects Alcohol may increase risk of hepatotoxicity fluorouracil (Adrucil, 5-FU) Food decreases absorption Not compatible with diazepam, doxorubicin, and methotrexate Inactivate live vaccines Severe cardiac problems if given with cisplatin 10 Cell Cycle Nonspecific Alkylating agents Nitrogen Mustard Derivatives mechlorethamine (Mustargen) Nitrosoureas carmustine (BCNU) (Gliadel) Platinum-Based Drugs cisplatin (Platinol-AQ) Anitineoplastic Antibiotics bleomycin sulfate (Blenoxane) 11 Alkylating Drugs Interferes with the process of cell division of malignant and normal cells. Binds with DNA, causing breaks and prevents DNA replication. Makes the cell a more alkaline environment, thus damage to the cell. Highly toxic. Many unpleasant/dangerous side effects. 12 4

5 Alkylating Drugs Interactions Cisplatin (Platinol) decreases the effects of antigout drugs. Used with aminoglycosides may increase nephrotoxicity & ototoxicity. Used with loop diuretics may increase risk for ototoxicity. Prior to Cisplatin hydrate with 1-2 L of IV fluid Mechlorethamine (Mustargen) Vesicant 13 Antineoplastic Antibiotics No anti-infective ability. Interfere with DNA & RNA synthesis delay/inhibit cell division May decrease antibody response to live virus vaccines. Increased risk of bleeding when administered with ASA, warfarin, heparin and NSAIDS Additive bone marrow depressant when given with other antineoplastics. 14 Antineoplastic Antibiotics Interactions bleomycin sulfate (Blenoxane) May decrease plasma serum digoxin levels Increased risk of toxicity when administered with cisplatin. Pulmonary toxicity may occur with other antineoplastic drugs. dactinomycin (Cosmegen) Potentiates skin/gi reactions of radiation tx doxorubicin (Adriamycin) Cardiotoxicity Hyperuricemia Encourage po of 2000mL per day 15 5

6 Adverse Reactions Potentially toxic associated with serious adverse reactions. Immediate During Cycle of therapy Long term 16 Adverse Reactions Anitineoplastic drugs affect rapidly proliferating cell, both cancer cells and normal cell, so common adverse reactions are: Bone marrow depression Stomatitis Diarrhea Hair loss 17 Adverse Reactions Often dose dependent Severity may increase with repeated doses Pre-medicate in anticipation of these adverse reaction IV Fluids Electrolytes Antiemetics 18 6

7 Antineoplastic Drugs Contraindications Leukopenia Thrombocytopenia, Anemia Serious infections Serious renal disease Hypersensitivity to drug Pregnancy 19 Cytoprotective Agents Drugs given with antineoplastic drugs to protect normal cells or organs or counteract the adverse affects, thus preventing irreversible harm. Allopurinol Leucovorin 20 Herbal Alert Shiitake Mushrooms Lentinan Benefits Mild Side Effects 21 7

8 Nursing Assessment Preadministration assessment Stage, location, and type of cancer Overall physical condition Psychosocial Previous or concurrent treatments Medical history Knowledge Family support, financial concerns ect. Initial physical assessment (baseline data) 22 Nursing assessment Preadministration Some Anitineoplastic drugs require treatment measure before the administration. Examples: Antiemetics Hydration Patient receive 1-2 Liters of IV fluids before administration of cisplatin (Platinol) 23 Nursing Assessment Ongoing assessment: Pt general condition Response to treatment Adverse reactions Infection Labs CBC Kidney function test 24 8

9 Nursing Assessment Leukopenia: Leukocyte count less than 5000/mm 3 (normal ,000/mm 3 ) Neutrophils are major component of the inflammatory process and defense against bacterial infection Thrombocytopenia: Low platelets or thrombocytes less than 100,000/mm 3 (normal 150, ,000/mm 3 ) Know your Nursing interventions? 25 Nursing Assessment (anemia) Hematocrit Male: 40-54% Female: 37-47% Hemoglobin Male: g/dl Female: g/dl Red Cell Count Male: million/ml Female: million/ml 26 NADIR The lowest counts after chemo tx, before recovery begins. Drugs to treat NADIR Neupogen Neulasta 27 9

10 Planning Optimal response to therapy Management of adverse reactions Patient understanding of therapy 28 Implementation Care of the Patient Settings Written guidelines & protocols 29 Safety Table 51.1 & Display 51.5, pg 525 Wear disposable gloves Preparation 30 10

11 Routes of Administration Oral Convenient and non-invasive Most are absorbed well through the GI tract Taken at home Examples: Xeloda Temodar 31 Parenteral Administration IM SQ IV 32 Managing Adverse Reactions Alopecia Anorexia Bone marrow suppression 33 11

12 Managing Adverse Reactions Nausea and Vomiting Stomatitis Diarrhea Tissue integrity Anxiety 34 Vesicants Some antineoplastic drugs are vesicants Mustargen Adriamycin Vinblastine Vincristine Vesicants cause tissue necrosis when they infiltrate or extravasate out of the blood vessel and into the soft tissue Vesicants are usually given through a central line Must keep an extravasation kit containing all material to manage an extravasation, along with policies and procedure guideline. 35 Patient and Family Education Must educate patient and family on the basics Take medication as directed Follow all recommendations No OTC drugs without consulting MD Know the name of the medication Never omit a dose Watch for adverse reactions Keep all appointments Emotional support 36 12

13 Important Read ALL Nursing Alerts, Boxes, Displays, & Tables Study Guide 37 13

Hospice Skills Checklist

Hospice Skills Checklist _ XXX-XX- Print Name Last 4 of SS # Date Completed Directions Please circle a value for each question to provide us and the interested facilities with an assessment of your clinical experience. These values

More information

Oncology Skills Checklist

Oncology Skills Checklist _ XXX-XX- Print Name Last 4 of SS # Date Completed Directions Please circle a value for each question to provide us and the interested facilities with an assessment of your clinical experience. These values

More information

DRUG EXTRAVASATION. Vesicants. Irritants

DRUG EXTRAVASATION. Vesicants. Irritants DRUG EXTRAVASATION Vesicants Irritants Vesicants Antineoplastic drugs Amsacrine Dactinomycin Daunorubicin Docetaxel (rare) Doxorubicin Epirubicin Idarubicin Mechlorethamine Mitomycin Oxaliplatin (rare)

More information

Medication Review. Cancer Chemotherapy Drugs. Pharmacy Technician Training Systems Passassured, LLC

Medication Review. Cancer Chemotherapy Drugs. Pharmacy Technician Training Systems Passassured, LLC Medication Review Cancer Chemotherapy Drugs Pharmacy Technician Training Systems Passassured, LLC Medication Review, Cancer Chemotherapy Drugs PassAssured's Pharmacy Technician Training Program Medication

More information

Chemotherapy and the development of novel therapeutics

Chemotherapy and the development of novel therapeutics SCPA607-Pathobiology and mechanisms of cancer Chemotherapy and the development of novel therapeutics Somphong Narkpinit, M.D. Department of Pathobiology Faculty of Science Mahidol University E-mail : somphong.nar@mahidol.ac.th

More information

DRUGS FOR NEOPLASIA. Chapter 37

DRUGS FOR NEOPLASIA. Chapter 37 DRUGS FOR NEOPLASIA Chapter 37 Keywords- You tell Me! Cancer dz characterized by abnormal, uncontrolled cell division Tumor swelling, abnormal enlargement or mass of tissue Carcinogen any substance or

More information

Fundamentals of Pharmacology for Veterinary Technicians Chapter 20

Fundamentals of Pharmacology for Veterinary Technicians Chapter 20 Figure 20-1 Figure 20-2 Figure 20-3A Figure 20-3B Figure 20-4 Table 20-1 Antineoplastic Agents Used for Chemotherapy in Animals Drug Type Drug Category Examples Cell-Cycle Effect CCNS Alkylating agents:

More information

Cancer SLO Practice (online set) Page 1 of 5

Cancer SLO Practice (online set) Page 1 of 5 Cancer SLO Practice (online set) Page 1 of 5 1. Aranesp is? A. Darbepoetin alfa B. Filgrastim C. Epoetin alfa D. Sargramostim E. Pegfilgrastim 2. BCNU is? B. Cyclophosphamide 3. Bleomycin is a natural

More information

Chapter 37. Media Directory. Tumor (neoplasm) Cancer (carcinoma) Causes of Cancer. Drugs for Neoplasia

Chapter 37. Media Directory. Tumor (neoplasm) Cancer (carcinoma) Causes of Cancer. Drugs for Neoplasia Chapter 37 Media Directory Drugs for Neoplasia Slide 39 Slide 41 Cyclophosphamide Animation Methotrexate Animation Upper Saddle River, New Jersey 07458 All rights reserved. Cancer (carcinoma) Tumor (neoplasm)

More information

Anti-cancer drugs. Introduction : Body : 1) Alkylating Agents

Anti-cancer drugs. Introduction : Body : 1) Alkylating Agents Anti-cancer drugs Introduction : In this journal I will try to explain what is anti-cancer agents, how they work, how can they inhibit the growth of tumor and what is the advantages and disadvantages of

More information

3/9/2017. Chapter 56. Care of the Patient with Cancer. Cancer Rates in the US. Carcinogenesis

3/9/2017. Chapter 56. Care of the Patient with Cancer. Cancer Rates in the US. Carcinogenesis Chapter 56 Care of the Patient with Cancer All items and derived items 2015, 2011, 2006 by Mosby, Inc., an imprint of Elsevier Inc. All rights reserved. Cancer Rates in the US 1 in 2 men and 1 in 3 women

More information

Cancer Chemotherapy. Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan December 2018

Cancer Chemotherapy. Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan December 2018 Cancer Chemotherapy Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan December 2018 االدوية Polyfunctional Alkylating Agents االستخالبية متعددة الوظائف Not cell cycle-specific.

More information

Cisplatin and Gemcitabine (bladder)

Cisplatin and Gemcitabine (bladder) Cisplatin and Gemcitabine (bladder) Indication Palliative therapy for locally advanced or metastatic bladder cancer in patients with good renal function. Palliative therapy for urothelial transitional

More information

CeeNU (lomustine) Capsules

CeeNU (lomustine) Capsules CeeNU (lomustine) Capsules WARNINGS CeeNU (lomustine) should be administered under the supervision of a qualified physician experienced in the use of cancer chemotherapeutic agents. Bone marrow suppression,

More information

Docetaxel. Class: Antineoplastic agent, Antimicrotubular, Taxane derivative.

Docetaxel. Class: Antineoplastic agent, Antimicrotubular, Taxane derivative. Docetaxel Class: Antineoplastic agent, Antimicrotubular, Taxane derivative. Indications: -Breast cancer: -Non small cell lung cancer -Prostate cancer -Gastric adenocarcinoma _Head and neck cancer Unlabeled

More information

Pfizer Laboratories (Pty) Ltd P&U Etoposide CSV Range Approved PI: 12 Sep 2005 Page 1 of 5

Pfizer Laboratories (Pty) Ltd P&U Etoposide CSV Range Approved PI: 12 Sep 2005 Page 1 of 5 Approved PI: 12 Sep 2005 Page 1 of 5 SCHEDULING STATUS: S4 PROPRIETARY NAME (and dosage form): P&U ETOPOSIDE CSV 100 mg/5 ml INJECTION (INJECTION CONCENTRATE FOR INTRAVENOUS INFUSION) P&U ETOPOSIDE CSV

More information

Cisplatin and Vinorelbine and radiotherapy (NSCLC)

Cisplatin and Vinorelbine and radiotherapy (NSCLC) Cisplatin and Vinorelbine and radiotherapy (NSCLC) Indication First-line chemotherapy for use with concomitant radical radiotherapy for early or locally advanced non-small cell carcinoma (NSCLC) ICD-10

More information

Cisplatin and Vinorelbine and radiotherapy (NSCLC)

Cisplatin and Vinorelbine and radiotherapy (NSCLC) Cisplatin and Vinorelbine and radiotherapy (NSCLC) Indication First-line chemotherapy for use with concomitant radical radiotherapy for early or locally advanced non-small cell carcinoma (NSCLC) ICD-10

More information

through the cell cycle. However, how we administer drugs also depends on the combinations that we give and the doses that we give.

through the cell cycle. However, how we administer drugs also depends on the combinations that we give and the doses that we give. Hello and welcome to this lecture. My name is Hillary Prescott. I am a Clinical Pharmacy Specialist at The University of Texas MD Anderson Cancer Center. My colleague, Jeff Bryan and I have prepared this

More information

Cisplatin and Pemetrexed (NSCLC, mesothelioma)

Cisplatin and Pemetrexed (NSCLC, mesothelioma) Cisplatin and Pemetrexed (NSCLC, mesothelioma) Indication First-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) if the histology of the tumour has been confirmed as

More information

Calcium (Ca 2+ ) mg/dl

Calcium (Ca 2+ ) mg/dl Quick Guide to Laboratory Values Use this handy cheat-sheet to help you monitor laboratory values related to fluid and electrolyte status. Remember, normal values may vary according to techniques used

More information

Year III Pharm D. Dr. V. Chitra

Year III Pharm D. Dr. V. Chitra Year III Pharm D. Dr. V. Chitra 50.2 Rang Etiolopathology Cell Cycle = Growth, Division 18_01_cell_cycle.jpg Characteristics of Cancer Cells The problem: Cancer cells divide rapidly (cell cycle is accelerated)

More information

VI.2 Elements for a Public Summary VI.2.1 Overview of Disease Epidemiology Acute Nausea and Vomiting (N&V) Etiologies:

VI.2 Elements for a Public Summary VI.2.1 Overview of Disease Epidemiology Acute Nausea and Vomiting (N&V) Etiologies: VI.2 Elements for a Public Summary VI.2.1 Overview of Disease Epidemiology Acute Nausea and Vomiting (N&V) Incidence: The incidence of acute and delayed N&V was investigated in highly and moderately emetogenic

More information

DBL VINBLASTINE INJECTION

DBL VINBLASTINE INJECTION DBL VINBLASTINE INJECTION NAME OF MEDICINE Vinblastine Injection DESCRIPTION DBL Vinblastine Sulfate B.P. is the sulfate of an alkaloid, occurring in the Vinca rosea Linn., (a common, flowering herb).

More information

2. Mitotic Spindle Inhibitors (modulators of tubulin polymerisation) 3. Antimetabolites (anti-folates, pyrimidine and purine analogues)

2. Mitotic Spindle Inhibitors (modulators of tubulin polymerisation) 3. Antimetabolites (anti-folates, pyrimidine and purine analogues) CANCER DRUG CLASSES The classes of drugs currently used in the cancer clinic are 1. DNA Binding Agents (intercalating and alkylating agents) 2. Mitotic Spindle Inhibitors (modulators of tubulin polymerisation)

More information

Anticancer Drugs. Cytotoxic drugs Antineoplastic agents

Anticancer Drugs. Cytotoxic drugs Antineoplastic agents Anticancer Drugs Cytotoxic drugs Antineoplastic agents 1 Principles of Cancer Chemotherapy Cancer chemotherapy strives to cause a lethal cytotoxic event or apoptosis in the cancer cells that can arrest

More information

APPROVED PACKAGE INSERT P&U CISPLATIN CSV RANGE

APPROVED PACKAGE INSERT P&U CISPLATIN CSV RANGE Approved PI: 24 Aug 2012 Page 1 of 12 APPROVED PACKAGE INSERT P&U CISPLATIN CSV RANGE SCHEDULING STATUS: S4 PROPRIETARY NAME (and dosage form): P&U CISPLATIN CSV 10 mg/10 ml INJECTION P&U CISPLATIN CSV

More information

CISPLATIN Chemo-radiation regimen Gynaecological Cancer

CISPLATIN Chemo-radiation regimen Gynaecological Cancer Systemic Anti Cancer Treatment Protocol CISPLATIN Chemo-radiation regimen Gynaecological Cancer PROCTOCOL REF: MPHAGYNCIX (Version No: 1.0) Approved for use in: Locally advanced cervical cancer (adjuvant/curative)

More information

Special pediatric considerations are noted when applicable, otherwise adult provisions apply.

Special pediatric considerations are noted when applicable, otherwise adult provisions apply. DRUG NAME: Lomustine SYNONYM(S): CCNU 1 COMMON TRADE NAME(S): CeeNU CLASSIFICATION: alkylating agent Special pediatric considerations are noted when applicable, otherwise adult provisions apply. MECHANISM

More information

CHEMOTHERAPY/ ANTICANCER DRUGS/ NEOPLASTIC AGENTS

CHEMOTHERAPY/ ANTICANCER DRUGS/ NEOPLASTIC AGENTS CHEMOTHERAPY/ 1 Oncology, Misc, Vaccines ANTICANCER DRUGS/ NEOPLASTIC AGENTS Important Terms: Cancer: A group of diseases involving abnormal cell growth with the potential to invade or spread to other

More information

Chapter 28. Media Directory. Hematopoiesis. Regulation of Hematopoiesis. Erythropoietin. Drugs for Hematopoietic Disorders

Chapter 28. Media Directory. Hematopoiesis. Regulation of Hematopoiesis. Erythropoietin. Drugs for Hematopoietic Disorders Chapter 28 Drugs for Hematopoietic Disorders Slide 35 Media Directory Epoetin Alfa Animation Upper Saddle River, New Jersey 07458 All rights reserved. Hematopoiesis Figure 28.1 Hematopoiesis Process of

More information

Oxaliplatin and Gemcitabine

Oxaliplatin and Gemcitabine Oxaliplatin and Gemcitabine Indication Palliative treatment for relapsed metastatic seminoma, non seminoma or combined tumours. ICD-10 codes Codes pre-fixed with C38, C48, C56, C62, C63, C75.3. Regimen

More information

Adverse effects of anticancer drugs (Antimetabolites agents, Alkylating agents, Antimicrotubule agents, Miscellaneous agents, Immune therapies and

Adverse effects of anticancer drugs (Antimetabolites agents, Alkylating agents, Antimicrotubule agents, Miscellaneous agents, Immune therapies and 35 Adverse effects of anticancer drugs (Antimetabolites agents, Alkylating agents, Antimicrotubule agents, Miscellaneous agents, Immune therapies and Biologically directed therapies ) 1 1- Nausea and vomiting

More information

Pharmacology. Cell cycle

Pharmacology. Cell cycle Objectives: To define chemotherapy To define the common classes of drugs used and mechanism of action To identify dermatologic side effects of chemotherapeutic drugs Chemotherapy Definition: the treatment

More information

Carboplatin and Fluorouracil

Carboplatin and Fluorouracil Carboplatin and Fluorouracil Indication Palliative chemotherapy for recurrent or metastatic head and neck squamous cell cancer for patients where cisplatin and / or cetuximab are not appropriate. Performance

More information

Oncology 101. Marianne Davies, RN, APRN Yale Cancer Center September 2006

Oncology 101. Marianne Davies, RN, APRN Yale Cancer Center September 2006 Oncology 101 Marianne Davies, RN, APRN Yale Cancer Center September 2006 Fundamentals Biology of Cancer Diagnosis Pathology Principles of therapy Schedules/Delivery Toxicities Staging Evaluation of response

More information

Anticancer Drugs. Cytotoxic drugs Antineoplastic agents

Anticancer Drugs. Cytotoxic drugs Antineoplastic agents Anticancer Drugs Cytotoxic drugs Antineoplastic agents 1 Principles of Cancer Chemotherapy Cancer chemotherapy strives to cause a lethal cytotoxic event or apoptosis in the cancer cells that can arrest

More information

BCCA Protocol Summary for Treatment of Advanced Squamous Cell Carcinoma of the Head and Neck Cancer Using Fluorouracil and Platinum

BCCA Protocol Summary for Treatment of Advanced Squamous Cell Carcinoma of the Head and Neck Cancer Using Fluorouracil and Platinum BCCA Protocol Summary for Treatment of Advanced Squamous Cell Carcinoma of the Head and Neck Cancer Using Fluorouracil and Platinum Protocol Code: Tumour Group: Contact Physician: HNAVFUP Head and Neck

More information

For the use only of a Registered Medical Practitioner or a Hospital or a Laboratory

For the use only of a Registered Medical Practitioner or a Hospital or a Laboratory For the use only of a Registered Medical Practitioner or a Hospital or a Laboratory Leucovorin Calcium Injection Zovorin TM Composition: Leucovorin Calcium Injection IP 50mg/5ml Each ml contains: Leucovorin

More information

Cancer Chemotherapy. Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan December 2018

Cancer Chemotherapy. Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan December 2018 Cancer Chemotherapy Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan December 2018 Modalities of Cancer Chemotherapy Curative: Only in 10-15% of cases. In certain disseminated

More information

Cancer Incidence and Mortality

Cancer Incidence and Mortality Cancer Incidence and Mortality Cancer is a common disease. One in three people in the Western World contract cancer and one in four die from it. The cure rate is 50% Cancer is strongly age-related, the

More information

X M/ (R) Dose adjusted (DA)-EPOCH-R

X M/ (R) Dose adjusted (DA)-EPOCH-R X M/ (R) adjusted (DA)-EPOCH-R Indication High-risk CD20+ diffuse large B cell lymphoma especially C-MYC and BCL-2 activated (i.e. double hit lymphoma) and mediastinal sclerosing (thymic) large B cell

More information

*Combination therapy: *Cancer drugs are divided into groups: I) DNA binding agents (Intercalating and Alkylating agents) 2 types: Doxorubicin

*Combination therapy: *Cancer drugs are divided into groups: I) DNA binding agents (Intercalating and Alkylating agents) 2 types: Doxorubicin *Combination therapy: - Cancer is heterogeneous, and resistant anticancer drugs are common, so combination of drugs together is needed in order to attack cancer. *Cancer drugs are divided into groups:

More information

NCCP Chemotherapy Protocol. INDICATION ICD10 Protocol Code Hodgkin s Lymphoma C a

NCCP Chemotherapy Protocol. INDICATION ICD10 Protocol Code Hodgkin s Lymphoma C a ABVD THERAPY INDICATIONS FOR USE: INDICATION ICD10 Protocol Code Hodgkin s Lymphoma C81 00290a ELIGIBILTY: Indications as above ECOG 0-3. Patients with an ECOG 4 may be considered for treatment at the

More information

MUSCULOSKELETAL PHARMACOLOGY. A story of the inflamed

MUSCULOSKELETAL PHARMACOLOGY. A story of the inflamed MUSCULOSKELETAL PHARMACOLOGY A story of the inflamed 1 INFLAMMATION Pathophysiology Inflammation Reaction to tissue injury Caused by release of chemical mediators Leads to a vascular response Fluid and

More information

Cisplatin and Gemcitabine Bladder Cancer: Full and split dose

Cisplatin and Gemcitabine Bladder Cancer: Full and split dose Systemic Anti Cancer Treatment Protocol Cisplatin and Gemcitabine Bladder Cancer: Full and split dose PROCTOCOL REF: MPHAUROCIG (Version No: 1.0) Approved for use in: Neoadjuvant and palliative indications

More information

Cisplatin and Fluorouracil

Cisplatin and Fluorouracil Cisplatin and Fluorouracil Indication Neo-adjuvant treatment of nasopharyngeal head and neck cancer (stage II-IV) or bulky disease at other head and neck sites. Performance Status 0-1 ICD-10 codes Codes

More information

AXITAB-CV TAB. COMPOSITION :

AXITAB-CV TAB. COMPOSITION : AXITAB-CV TAB. COMPOSITION : Each film coated tablet contains: Cefuroxime Axetil I.P. Eq. to Anhydrous 500mg. Potassium Clavulanate Diluted I.P. Eq. to Clavulanic Acid 125mg DESCRIPTION : Cefuroxime Axetil

More information

Cisplatin and Fluorouracil (palliative)

Cisplatin and Fluorouracil (palliative) Cisplatin and Fluorouracil (palliative) Indication Palliative chemotherapy for recurrent or metastatic head and neck squamous cell cancer where combination treatment with cetuximab is not indicated. PS0-1

More information

Understanding Blood Tests

Understanding Blood Tests PATIENT EDUCATION patienteducation.osumc.edu Your heart pumps the blood in your body through a system of blood vessels. Blood delivers oxygen and nutrients to all parts of the body. It also carries away

More information

Take 25 mg every 6 hours as needed for 3 days To protect the bladder from infection or bleeding

Take 25 mg every 6 hours as needed for 3 days To protect the bladder from infection or bleeding How do I prepare for my first infusion? You will need to have the following tests done: 1. Complete Blood Count (CBC), electrolytes labs 2. BUN/Creatinine labs (tests to monitor kidney function) 3. Liver

More information

Chemotherapy and its side effects.

Chemotherapy and its side effects. Chemotherapy and its side effects. Maria Ronson Lead Chemotherapy Nurse Learning outcomes How it works on cells terminology. Understand and learn about side effects of chemotherapy. Management of side

More information

R-IDARAM. Dexamethasone is administered as an IV infusion in 100mL sodium chloride 0.9% over 30 minutes.

R-IDARAM. Dexamethasone is administered as an IV infusion in 100mL sodium chloride 0.9% over 30 minutes. R-IDARAM Indication Secondary CNS lymphoma ICD-10 codes Codes with a prefix C85 Regimen details Day Drug Dose Route 1 Rituximab 375mg/m 2 IV infusion 1 Methotrexate 12.5mg Intrathecal 1 Cytarabine 70mg

More information

Cancer diagnosis and treatments- brief overview of the changing paradigm.

Cancer diagnosis and treatments- brief overview of the changing paradigm. Cancer diagnosis and treatments- brief overview of the changing paradigm. Pranshu Bansal MD New Mexico Cancer Center Identifying cancer in clinic Most common cancers are lung, breast, colon, prostate and

More information

*Monitor for significant side effects, especially symptoms of neurological or cardiovascular events.

*Monitor for significant side effects, especially symptoms of neurological or cardiovascular events. Assessment Prior to administration: Obtain complete health history including allergies, drug history, and possible drug reactions Assess reason for drug administration such as presence/history of anemia

More information

THE CLATTERBRIDGE CANCER CENTRE NHS FOUNDATION TRUST

THE CLATTERBRIDGE CANCER CENTRE NHS FOUNDATION TRUST Outpatient Anti Cancer Treatment Handbook LCV Lomustine, Cisplatin, Vincristine Packer Regimen Repeated every 6 weeks for a maximum of 6 cycles Approved for use in: Medulloblastoma adjuvant therapy Dosage:

More information

Cisplatin / 5-Fluorouracil (+ Trastuzumab) in Gastric Cancer

Cisplatin / 5-Fluorouracil (+ Trastuzumab) in Gastric Cancer Cisplatin / 5-Fluorouracil (+ Trastuzumab) in Gastric Cancer Indication: Confirmed HER2-positive (3+ or FISH+) metastatic adenocarcinoma of the stomach or gastro-oesophageal junction. For Trastuzumab doses

More information

VIP (Etoposide, Ifosfamide and Cisplatin)

VIP (Etoposide, Ifosfamide and Cisplatin) VIP (Etoposide, Ifosfamide and Cisplatin) Indication First line treatment for metastatic seminoma, non seminoma or combined tumours where bleomycin is contra-indicated. Usually used for patients with intermediate

More information

Cisplatin / 5-Fluorouracil for Vulval Cancer

Cisplatin / 5-Fluorouracil for Vulval Cancer Cisplatin / 5-Fluorouracil for Vulval Cancer Indication: Palliative therapy in patients with Vulval Cancer Regimen details: Cisplatin 75mg/m 2 (*) IV 5-Fluorouracil (5-FU) 1000mg/m 2 /24 hours IV D4 (*)Consider

More information

Leucovorin Calcium Tablets USP, 5 mg, 10 mg, 15 mg, and 25 mg

Leucovorin Calcium Tablets USP, 5 mg, 10 mg, 15 mg, and 25 mg Leucovorin Calcium Tablets USP, 5 mg, 10 mg, 15 mg, and 25 mg Rx only DESCRIPTION Leucovorin Calcium Tablets USP contain either 5 mg, 10 mg, 15 mg or 25 mg leucovorin as the calcium salt of N-[4-[[(2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl]

More information

PREMEDICATIONS: Antiemetic protocol for highly emetogenic chemotherapy. May not need any antiemetic with

PREMEDICATIONS: Antiemetic protocol for highly emetogenic chemotherapy. May not need any antiemetic with BCCA Protocol Summary for Palliative Therapy of Metastatic or Locally Advanced Gastric, Gastroesophageal Junction Adenocarcinoma, Esophageal Squamous Cell Carcinoma, or Anal Squamous Cell Carcinoma using

More information

Cisplatin and Fluorouracil (head and neck)

Cisplatin and Fluorouracil (head and neck) Cisplatin and Fluorouracil (head and neck) Indication Palliative chemotherapy for recurrent or metastatic head and neck squamous cell cancer where combination treatment with cetuximab is not indicated.

More information

MATRIX (Methotrexate, Cytarabine, Thiotepa and Rituximab)

MATRIX (Methotrexate, Cytarabine, Thiotepa and Rituximab) MATRIX (Methotrexate, Cytarabine, Thiotepa and Rituximab) Indication First line treatment of primary CNS lymphoma. ICD-10 codes Codes with a prefix C85 Regimen details Day Drug Dose Route 1 and 6 Rituximab

More information

Carboplatin Injection BP KEMOCARB

Carboplatin Injection BP KEMOCARB WARNING: For the use only of a Registered Medical Practitioner or a Hospital or a Laboratory Carboplatin Injection BP KEMOCARB Carboplatin Injection should be administered under the supervision of a qualified

More information

Cancer Epidemiology, Manifestations, and Treatment

Cancer Epidemiology, Manifestations, and Treatment Cancer Epidemiology, Manifestations, and Treatment Chapter 10 Environmental Risk Factors Tobacco Ø Multipotent carcinogenic mixture Ø Linked to cancers of the lung, lower urinary tract, digestive tract,

More information

Index. Note: Page numbers of article titles are in boldface type.

Index. Note: Page numbers of article titles are in boldface type. Note: Page numbers of article titles are in boldface type. A Abdominal tumors, in children, 530 531 Alkalinization, in tumor lysis syndrome, 516 Allopurinol, in tumor lysis syndrome, 515 Anaphylaxis, drug

More information

Introduction to Antineoplastic Prescribing

Introduction to Antineoplastic Prescribing Introduction to Antineoplastic Prescribing Robert Bradbury, R.Ph., BCPS Clinical Coordinator H. Lee Moffitt Cancer Center Objectives Meet the following goals concerning antineoplastic prescribing: Understand

More information

Why do patients take herbs and nutritional supplements?

Why do patients take herbs and nutritional supplements? Why do patients take herbs and nutritional supplements? Dissatisfaction with conventional medicine > Relieve cancer-related symptoms > Treat adverse effects of anticancer drugs > Treat cancer > Promote

More information

NURSING PROCESS FOCUS: Patients Receiving Amphotericin B (Fungizone, Abelcet)

NURSING PROCESS FOCUS: Patients Receiving Amphotericin B (Fungizone, Abelcet) NURSING PROCESS FOCUS: Patients Receiving Amphotericin B (Fungizone, Abelcet) ASSESSMENT Prior to administration: Obtain complete health history including allergies, drug history, and possible drug interactions.

More information

SARASOTA MEMORIAL HOSPITAL

SARASOTA MEMORIAL HOSPITAL SARASOTA MEMORIAL HOSPITAL TITLE: NURSING PROCEDURE DATE: REVIEWED: PAGES: 03/86 7/18 1 of 13 PS1094 ISSUED FOR: Nursing RESPONSIBILITY: RN Chemo Qualified PURPOSE: To provide the RN with specific steps

More information

Routine monitoring requirements for your mcrpc patients on Xofigo

Routine monitoring requirements for your mcrpc patients on Xofigo XOFIGO IS INDICATED for the treatment of patients with castration-resistant prostate cancer (CRPC), symptomatic bone metastases and no known visceral metastatic disease. Introduce Xofigo at the first sign

More information

BRLAACDT. Protocol Code. Breast. Tumour Group. Dr. Karen Gelmon. Contact Physician

BRLAACDT. Protocol Code. Breast. Tumour Group. Dr. Karen Gelmon. Contact Physician BCCA Protocol Summary for Treatment of Locally Advanced Breast Cancer using DOXOrubicin and Cyclophosphamide followed by DOCEtaxel and Trastuzumab (HERCEPTIN) Protocol Code Tumour Group Contact Physician

More information

Cisplatin / Paclitaxel Gynaecological Cancer

Cisplatin / Paclitaxel Gynaecological Cancer Systemic Anti Cancer Treatment Protocol Cisplatin / Paclitaxel Gynaecological Cancer PROCTOCOL REF: MPHAGYNCIP (Version No: 1.0) Approved for use in: First line treatment for stage Ib-IV with minimal residual

More information

Siklos (hydroxyurea) NEW PRODUCT SLIDESHOW

Siklos (hydroxyurea) NEW PRODUCT SLIDESHOW Siklos (hydroxyurea) NEW PRODUCT SLIDESHOW Introduction Brand name: Siklos Generic name: Hydroxyurea Pharmacological class: Antimetabolite Strength and Formulation: 100mg, 1000mg+; tabs; +triple-scored

More information

Cisplatin / 5-Fluorouracil for Neoadjuvant Oesophageal Cancer

Cisplatin / 5-Fluorouracil for Neoadjuvant Oesophageal Cancer Cisplatin / 5-Fluorouracil for Neoadjuvant Oesophageal Cancer Indication: Neoadjuvant therapy for resectable Oesophageal Cancer Regimen details: Cisplatin 80mg/m 2 IV 5-Fluorouracil (5-FU) 1000mg/m 2 /24

More information

THE CLATTERBRIDGE CANCER CENTRE NHS FOUNDATION TRUST. Systemic Anti Cancer Treatment Protocol. EDP + mitotane

THE CLATTERBRIDGE CANCER CENTRE NHS FOUNDATION TRUST. Systemic Anti Cancer Treatment Protocol. EDP + mitotane Systemic Anti Cancer Treatment Protocol EDP + mitotane PROCEDURE REF: MPHAHANEDP (Version No: 1.0) Approved for use in: Symptomatic treatment for advanced (unresectable, metastatic or relapsed) adrenocortical

More information

Routine monitoring requirements for your mcrpc patients on Xofigo

Routine monitoring requirements for your mcrpc patients on Xofigo XOFIGO IS INDICATED for the treatment of patients with castration-resistant prostate cancer (CRPC), symptomatic bone metastases and no known visceral metastatic disease. Introduce Xofigo at the first sign

More information

Cisplatin100 plus Radiotherapy for locally Advanced Squamous Cell Carcinoma Head and Neck

Cisplatin100 plus Radiotherapy for locally Advanced Squamous Cell Carcinoma Head and Neck Cisplatin100 plus Radiotherapy for locally Advanced Squamous Cell Carcinoma Head and Neck Indication: 1) Concomitant chemo-radiotherapy for locally advanced squamous cell carcinoma head and neck 2) Post-operative

More information

Updates in the Management of Anemia in Cancer. Taylor M. Ortiz, MD May 19, 2017

Updates in the Management of Anemia in Cancer. Taylor M. Ortiz, MD May 19, 2017 Updates in the Management of Anemia in Cancer Taylor M. Ortiz, MD May 19, 2017 Objectives Recall common causes of anemia in patients with cancer Understand risks/benefits of blood transfusion in patients

More information

PACKAGE LEAFLET: INFORMATION FOR THE USER Doxorubicin 2mg/ml Concentrate for solution for infusion Referred to in this leaflet as Doxorubicin 2mg/ml

PACKAGE LEAFLET: INFORMATION FOR THE USER Doxorubicin 2mg/ml Concentrate for solution for infusion Referred to in this leaflet as Doxorubicin 2mg/ml PACKAGE LEAFLET: INFORMATION FOR THE USER Doxorubicin 2mg/ml Concentrate for solution for infusion Referred to in this leaflet as Doxorubicin 2mg/ml Read all of this leaflet carefully before you start

More information

MCF: Mitomycin C / Cisplatin / PVI Fluorouracil for Advanced Oesophageal or Gastric Cancer

MCF: Mitomycin C / Cisplatin / PVI Fluorouracil for Advanced Oesophageal or Gastric Cancer MCF: Mitomycin C / Cisplatin / PVI Fluorouracil for Advanced Oesophageal or Gastric Cancer Indication: Second line palliative therapy for locally advanced or Metastatic Oesophageal or Gastric Cancer, especially

More information

Immunosuppressants. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia

Immunosuppressants. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia Immunosuppressants Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia Immunosuppressive Agents Very useful in minimizing the occurrence of exaggerated or inappropriate

More information

Carboplatin / Liposomal Doxorubicin CARBO/CAELYX Gynaecological Cancer

Carboplatin / Liposomal Doxorubicin CARBO/CAELYX Gynaecological Cancer Systemic Anti Cancer Treatment Protocol Carboplatin / CARBO/CAELYX Gynaecological Cancer PROCTOCOL REF: MPHAGYNCCX (Version No: 1.0) Approved for use in: Advanced ovarian cancer in women who have progressed

More information

Gemcitabine, Carboplatin and Bevacizumab (gynae)

Gemcitabine, Carboplatin and Bevacizumab (gynae) Gemcitabine, Carboplatin and Bevacizumab (gynae) Indication Second line advanced epithelial ovarian, fallopian tube or primary peritoneal cancer. WHO performance status 0 or 1. (Funding via the CDF) ICD-10

More information

Lipoplatin monotherapy for oncologists

Lipoplatin monotherapy for oncologists Lipoplatin monotherapy for oncologists Dr. George Stathopoulos demonstrated that Lipoplatin monotherapy against adenocarcinomas of the lung can have very high efficacy (38% partial response, 43% stable

More information

PRODUCT MONOGRAPH. Gemcitabine for Injection. 200 mg, 1 g and 2 g gemcitabine (as gemcitabine hydrochloride) per vial House Std. Antineoplastic Agent

PRODUCT MONOGRAPH. Gemcitabine for Injection. 200 mg, 1 g and 2 g gemcitabine (as gemcitabine hydrochloride) per vial House Std. Antineoplastic Agent PRODUCT MONOGRAPH Pr Gemcitabine for Injection 200 mg, 1 g and 2 g gemcitabine (as gemcitabine hydrochloride) per vial House Std. Antineoplastic Agent Accord Healthcare Inc. 3100, Steels Avenue East, Markham,

More information

Irinotecan Capecitabine (14 day regimen) (I-Cap)

Irinotecan Capecitabine (14 day regimen) (I-Cap) Systemic Anti Cancer Treatment Protocol Irinotecan (14 day regimen) (I-Cap) PROTOCOL REF: MPHAICAP (Version No: 1.0) Approved for use in: Advanced colorectal cancer first line Advanced colorectal cancer

More information

PARAPLATIN (carboplatin) for Injection, USP

PARAPLATIN (carboplatin) for Injection, USP Rx only PARAPLATIN (carboplatin) for Injection, USP WARNING PARAPLATIN (carboplatin) for Injection, USP should be administered under the supervision of a qualified physician experienced in the use of cancer

More information

MEDICATIONS: THE GOOD, THE BAD, THE UGLY

MEDICATIONS: THE GOOD, THE BAD, THE UGLY MEDICATIONS: THE GOOD, THE BAD, THE UGLY July 13, 2013 Dr. Tanaz Kermani Assistant Clinical Professor of Medicine, Division of Rheumatology, David Geffen School of Medicine UCLA Dr. Robert Spiera Professor

More information

Chemoradiation Interactions and Toxicity Management

Chemoradiation Interactions and Toxicity Management Chemoradiation Interactions and Toxicity Management Jonathan W. Thompson April 15, 2016 University of Alabama At Birmingham, Department of Radiation Oncology Radiation Oncology Associates of Acadiana,

More information

Oral: readily and completely absorbed. Highly lipid soluble, present in breast milk. Volume of distribution % within 96 hours

Oral: readily and completely absorbed. Highly lipid soluble, present in breast milk. Volume of distribution % within 96 hours Drug Monograph Drug Name Mechanism of Action and Pharmacokinetics Indications and Status Adverse ffects Dosing Administration Guidelines Special Precautions Interactions Recommended Clinical Monitoring

More information

HCX Herceptin, Cisplatin and Capecitabine

HCX Herceptin, Cisplatin and Capecitabine DRUG ADMINISTRATION SCHEDULE First Cycle Only: Day Drug Daily Dose Route Diluent Rate Sodium Chloride 0.9% 250 ml Infusion Fast Running Day 1 Furosemide 20mg IV bolus Via saline drip Trastuzumab 8mg/kg

More information

Breast Pathway Group Epirubicin & Cyclophosphamide x 4 followed by Carboplatin & Paclitaxel x 4 for Early Breast Cancer

Breast Pathway Group Epirubicin & Cyclophosphamide x 4 followed by Carboplatin & Paclitaxel x 4 for Early Breast Cancer Breast Pathway Group Epirubicin & Cyclophosphamide x 4 followed by Carboplatin & Paclitaxel x 4 for Early Breast Cancer Indication: Neoadjuvant therapy for patients with BRCA1/2 mutations EC Regimen details:

More information

Carboplatin / Gemcitabine Gynaecological Cancer

Carboplatin / Gemcitabine Gynaecological Cancer Systemic Anti Cancer Treatment Protocol Carboplatin / Gemcitabine Gynaecological Cancer PROCTOCOL REF: MPHAGYNCAG (Version No: 1.0) Approved for use in: Recurrent/metastatic endometrial carcinoma Previously

More information

4/9/18. Disclosure Information. Objectives. Overview of Neuroblastoma Management. I have no disclosures.

4/9/18. Disclosure Information. Objectives. Overview of Neuroblastoma Management. I have no disclosures. Overview of Neuroblastoma Management Lauren Martino, RN, MSN, CPNP Pediatric Surgery Nurse Practitioner Memorial Sloan-Kettering Cancer Center Disclosure Information I have no disclosures. Objectives Describe

More information

Cisplatin + Etoposide IV / Oral therapy followed by Chemo-radiotherapy in Small Cell Carcinoma of the Cervix

Cisplatin + Etoposide IV / Oral therapy followed by Chemo-radiotherapy in Small Cell Carcinoma of the Cervix Cisplatin + Etoposide IV / Oral therapy followed by Chemo-radiotherapy in Small Cell Carcinoma of the Cervix Indication: Neoadjuvant chemotherapy followed by Chemo-radiotherapy in Small Cell Carcinoma

More information

BRAJACTT. Protocol Code. Breast. Tumour Group. Dr. Karen Gelmon. Contact Physician

BRAJACTT. Protocol Code. Breast. Tumour Group. Dr. Karen Gelmon. Contact Physician BC Cancer Protocol Summary for Adjuvant Therapy for Breast Cancer using DOXOrubicin and Cyclophosphamide followed by PACLitaxel and Trastuzumab (HERCEPTIN) Protocol Code Tumour Group Contact Physician

More information

FEC-T (Fluorouracil, Epirubicin and Cyclophosphamide and Docetaxel)

FEC-T (Fluorouracil, Epirubicin and Cyclophosphamide and Docetaxel) FEC-T (Fluorouracil, Epirubicin and Cyclophosphamide and Docetaxel) Indication Adjuvant or neo-adjuvant treatment for high risk early and locally advanced breast cancer. (NICE CG80) ICD-10 codes Codes

More information

PRODUCT MONOGRAPH GEMCITABINE INJECTION

PRODUCT MONOGRAPH GEMCITABINE INJECTION PRODUCT MONOGRAPH Pr GEMCITABINE INJECTION Concentrate Sterile Solution for Injection Gemcitabine (as Gemcitabine Hydrochloride) 40 mg gemcitabine per ml 200 mg/5 ml, 1 g/25 ml, 2 g/50 ml Antineoplastic

More information

EOF Regimen EOF. A - Regimen Name. Gastrointestinal - Esophagus Gastrointestinal - Gastric / Stomach. Intent Palliative. Evidence-Informed :

EOF Regimen EOF. A - Regimen Name. Gastrointestinal - Esophagus Gastrointestinal - Gastric / Stomach. Intent Palliative. Evidence-Informed : Regimen Monograph Regimen Name Drug Regimen Cycle Frequency Premedication and Supportive Measures Dose Modifications Adverse Effects Interactions Drug Administration and Special Precautions Recommended

More information